Subscribe and recieve updates on this company.

Text STOCKS to 72727 for mobile alerts

We are excited to present Therapix Biosciences Ltd (NASDAQ: TRPX).

Full DD Report for TRPX

You must become a subscriber to view this report.

Recent News from (NASDAQ: TRPX)

Clinical Stage Marijuana Focused Biotech Stocks Trend Higher In August
CORAL GABLES, FL / ACCESSWIRE / August 30, 2018 / Typically the stock market slows down toward the end of summer but this year that has not been the case. The markets are hitting all time highs and one of the top sectors leading the charge: biotechnology. Big pharma is weighing in on clinica...
Date: August, 30 2018 13:30
Premarket Gainers as of 9:05 am (08/30/2018)
KTWO +26%  on being acquired by Stryker. More news on: K2M Group Holdings, Inc., Therapix Biosciences, Network-1 Technologies, Inc., Stocks on the move, , Read more ...
Source: SeekingAlpha
Date: August, 30 2018 09:19
Midday Gainers / Losers (08/28/2018)
Gainers: AFMD +220% . ATAI +43% . STAF +30% . ASFI +26% . BRKS +27% . VVPR +19% . DSW +18% . CVM +17% . BILI +16% . ABIL +15% . More news on: Affimed Therapeutics, ATA Inc., Staffing 360 Solutions, Inc., Stocks on the move, , Read more ...
Source: SeekingAlpha
Date: August, 28 2018 12:45
Therapix Biosciences net loss improves in Q2
Therapix Biosciences ( TRPX ) Q2 results : Revenues: $0; Net Loss: ($1.2M) (+36.8%); Loss Per Share: ($0.35) (+68.2%); Quick Assets: $5.1M (-56.8%). More news on: Therapix Biosciences, Healthcare stocks news, Earnings news and commentary, , Read more ...
Source: SeekingAlpha
Date: August, 20 2018 09:00
Therapix Biosciences reports Q2 results
Therapix Biosciences (NASDAQ: TRPX ): Q2 GAAP EPADS of -$0.35. More news on: Therapix Biosciences, Earnings news and commentary, Healthcare stocks news, , Read more ...
Source: SeekingAlpha
Date: August, 20 2018 08:34


Last 5 Days Trading Activity

DateOpen PriceClose PriceHighLowVolume

Last 5 Days Short Activity

DateShort VolumeTotal VolumeShort PercentageShort Indicator

* Cover Mode

Short Analysis provided by Squeeze Report. Get a complete short report on TRPX.

About Therapix Biosciences Ltd (NASDAQ: TRPX)

Logo for Therapix Biosciences Ltd (NASDAQ: TRPX)

Therapix is a specialty pharmaceutical company focused on synthetic cannabinoid based therapies with attractive risk/return profiles that target large, high value, under served markets


Contact Information



Current Management

  • Elran Haber / CEO, VP, Business Development
    • Dr. Elran Haber served over than years collectively as Chairman and Board Director of several publicly traded, privately held companies e.g. Issta lines Group TASE , Amex Travel services Israel amp various associations, and has been a member on variety of board committees. Dr. Haber held key roles at various life science startups amp private investment firm, most recently as VP of Strategy amp Business Development at ClearFarma industries Ltd. Elran was a key lecturer in numerous Israeli s Ministry of health programs. Dr. Haber holds a PhD in Pharmaceutical Science from The Hebrew University of Jerusalem, and a MBA in Finance amp Financial Engineering from The Hebrew University of Jerusalem
  • Guy Goldin / CFO
    • Mr. Goldin holds a B.A in Accounting and Economics from Tel Aviv University graduated in honors and a MBA from Tel Aviv University expertise in finance , Participation in marketing consulting project in collaboration with the School of Business of Wharton Philadelphia. Mr. Goldin has over years of experience in a wide variety of managerial, financial, tax and accounting related positions. Mr. Goldin s most recent position are as CFO at PetroGroup Ltd and at BSP Ltd. Public companies traded in TASE. Prior to that, he served as a CFO at Critisence a biotech company and as a CPA at KPMG.
  • Doron Ben Ami / Chief Strategy Officer
    • Doron is a seasoned executive with more than years of management experience holding various leadership roles in the multinational pharmaceutical industry. Among Doron s roles were Associate Vice President of the Eastern Europe and Israel region at Merck, Managing Director of the Merck s subsidiary in Israel and the General Manager of Lundbeck, Israel. He is acting as a senior consultant at Harel Consulting, a US based business development advisory firm that connects innovative pharmaceutical companies with strategic partners and with leading local and regional companies in international markets.
  • Ascher Shmuelwitz / Chairman
    • Dr. Ascher Shmulewitz is a prolific inventor and serial entrepreneur in biomedical technologies. He has originated over two dozen life science companies including NeoVision, Labcoat, Arteria, Circulation, and XCardia, and has led of these companies to successful exits in less than a decade, mostly through M amp A transactions with large medical device companies. He has vast experience in the venture capital arena as an investor, manager and entrepreneur in dozens of companies and ventures. He cofounded San Francisco Science and the Incumed Group for seed investment, and is founder of Medgenesis Partners, an Israeli private investment firm and incubator that has invested in over a dozen ventures. Dr. Shmulewitz previously held senior executive positions at Advanced Technology Laboratories. He received an MD from Technion Medical School and PhD in Engineering from Tel Aviv University.
  • Amit Berger / Independent Director, Audit Committee Member, Compensation Committee Member
    • CEO at Dolphin Investments Ltd Independent Director at N.R. Spuntech Industries Ltd. And Itay Financial AA Investments Ltd. Chairman at Enter Holdings Ltd. Chairman at Berger Holdings DS Securities amp Investments Ltd BSc in Economics from Tel Aviv University
  • Donald P. Dizon /
  • Mark E. Groussman /
  • Zoar Heiblum / Independent Director, Audit Committee Member, Compensation Committee Member
    • Mr. Zohar Heiblum was cofounder of TeFen Ltd, a leading consulting firm in Israel. Since then, Zohar has been involved in various companies as investor, consultant, board member and active chairman. Zohar led turnarounds at various companies such as Orex which was sold to Kodak, Biosonix which executed a reverse merger with Neoprobe, MobileAccess Foxcom which was sold to Corning, Celtro Ltd as a spinoff from ECI Communication, and others. Zohar has a BSc in Industrial Engineering and MBA, both from Tel Aviv University.
  • Micha Jesselson / Director
    • Member of the Jesselson Family Office that operates form Tel Aviv amp NY Manages Jesselson Investments Ltd BA in Business from the Interdisciplinary Center IDC , Herzliya
  • Avi Meizler / Director
    • Mr. Avi Meizler has been an experienced businessman and entrepreneur in Brazil since in the fields of pharmaceuticals, engineering and construction. He was founder and President of Meizler Biopharma S.A. from until when the Belgian multinational pharmaceutical company UCB acquired of the company, and is Chairman of the Board and Vice President Business Development of the merged company Meizler UCB Biopharma S.A. Mr. Meizler is also cofounder and CEO of Advantech Bioscience Pharmaceutical Ltd that was established in , and is developing recombinant clotting factors.
  • David Silverman /
  • Stephen M. Simes / Director
    • Extensive experience as a board member and in the management of public biopharma companies in the U.S., including BioSante Pharmaceuticals, Inc., Unimed Pharmaceuticals, Inc. and more. His expertise includes product development, financing, M amp A and building successful management teams. Mr. Simes earned his MBA in Marketing and Finance from New York University and BSc in Chemistry at Brooklyn College of the City University of New York.
  • Yafit Stark / Director
    • Vice President, Chief Clinical Officer and Head of Oncology, Emerging Therapeutic Areas amp Biogenerics Innovative R amp D at Teva Years of Industrial Experience, building up the Global Clinical Infrastructures of Teva Worldwide Clinical Trials Department and responsible for the Clinical Development of Copaxone and Other Teva Products. Expertise in Global Clinical Development of various types of products in Broad Spectrum of Therapeutic Areas and Indications Pioneer in implementing new technologies in clinical development Director and a Member of Advisory Committee in several biotechnology companies. PhD in Pathology from Sackler School of Medicine

Current Share Structure

  • Market Cap: $5,145,473 - 05/18/2018
  • Issue and Outstanding: 46,355,614 - 03/15/2017
  • Float: 26,865,234 - 03/15/2017


Recent Filings from (NASDAQ: TRPX)

Report of foreign issuer rules 13a-16 and 15d-16 of the Securities Exchange Act
Filing Type: 6-KFiling Source: edgar
Filing Date: August, 20 2018
Prospectus filed under Rule 424(b)(2)
Filing Type: 424B2Filing Source: edgar
Filing Date: August, 09 2018
Report of foreign issuer rules 13a-16 and 15d-16 of the Securities Exchange Act
Filing Type: 6-KFiling Source: edgar
Filing Date: August, 08 2018
Notice from the SEC of registration effectiveness
Filing Type: EFFECTFiling Source: edgar
Filing Date: July, 20 2018
Amendment to a previously filed F-3
Filing Type: F-3/AFiling Source: edgar
Filing Date: July, 17 2018
Securities offered to employees under employee benefit plans
Filing Type: S-8Filing Source: edgar
Filing Date: June, 21 2018
Registration statement for certain foreign private issuers offered for certain transactions
Filing Type: F-3Filing Source: edgar
Filing Date: June, 20 2018
Report of foreign issuer rules 13a-16 and 15d-16 of the Securities Exchange Act
Filing Type: 6-KFiling Source: edgar
Filing Date: June, 14 2018
Report of foreign issuer rules 13a-16 and 15d-16 of the Securities Exchange Act
Filing Type: 6-KFiling Source: edgar
Filing Date: June, 06 2018
Report of foreign issuer rules 13a-16 and 15d-16 of the Securities Exchange Act
Filing Type: 6-KFiling Source: edgar
Filing Date: May, 17 2018



Daily Technical Chart for (NASDAQ: TRPX)

Daily Technical Chart for (NASDAQ: TRPX)

Stay tuned for daily updates and more on (NASDAQ: TRPX)

It most certainly could but even more important is the recent overwhelming interest in the company. Check out Investors Hub and search on Twitter

More to come on (NASDAQ: TRPX)

Do your DD and if you choose, be ready to go!


The Research: All source information contained in this email is from the public sources mentioned below.



Thank you

DD Report



Disclaimer: DD Report publishes reports providing information on selected companies. DD Report is not a registered investment advisor or broker-dealer. This report is provided as an information service only, and the statements and opinions in this report should not be construed as an offer or solicitation to buy or sell any security. DD Report accepts no liability for any loss arising from an investors reliance on or use of this report. An investment in TRPX is considered to be highly speculative and should not be considered unless a person can afford a complete loss of investment. DD Report has received no compensation for the publication and circulation of this report. DD Report does not own any shares of TRPX and does not buy, sell, or trade any shares of TRPX. This report contains forward-looking statements, which involve risks, and uncertainties that may cause actual results to differ materially from those set forth in the forward-looking statements. Copyright 2018 by DD Report. All rights reserved. Our Full Disclaimer: